Budd: I spent a lot of time on this stock because I believed and still believe in Berkeley Bio and its mission. BB was why I bought SK. After D. Gold was appointed director, which outcome delighted me, I re-entered the stock, but this time only with money I could afford to lose, given the risk the market itself has been telegraphing. Since the merger announcement, the stock has traded as if there were something wrong with the picture. If the merger is consummated and SKTO lands unscathed, I'll buy some more. Then, if the merger is approved by regulators, I'll go full tilt. I would rather pay more for less risk. Come what may to SKTO, I think GoldNApel are smart enough to have protected their IP, which represents to some extent their life work, through built-in safeguards.